ストックスクリーナーアプリを入手
1.77
5.85%
-0.11
アフターアワーズ：
1.79
0.02
+1.13%
Ac Immune Sa (ACIU) 最新ニュース
AC Immune reports Phase II trial of ACI-7104.056 - The Pharma Letter
AC Immune’s Strategic Advances and Financial Highlights - TipRanks
AC Immune (ACIU) Shares Surge on Promising Parkinson's Trial Res - GuruFocus
AC Immune Announces Positive Interim Data From Early Parkinson's Disease Study - Nasdaq
AC Immune stock gains on Parkinson’s data (ACIU:NASDAQ) - Seeking Alpha
AC Immune announces additional data from Phase 2 study of VacSYn clinical trial - TipRanks
AC Immune Reports Further Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson's Disease - The Manila Times
AC Immune SAACI-7104.056 Is Well Tolerated With No Safety Issues Reported To Date - MarketScreener
AC Immune Reports Further Positive Interim Results from - GlobeNewswire
AC Immune Reports Further Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson’s Disease - GlobeNewswire Inc.
Benign Growth For AC Immune SA (NASDAQ:ACIU) Underpins Stock's 26% Plummet - simplywall.st
AC Immune To Showcase Innovations In Active Immunotherapies - Evrim Ağacı
AC Immune Announces Upcoming Presentations and Industry Symposium on Active Immunotherapies at AD/PD™ 2025 - The Manila Times
AC Immune SA to Highlight Advanced Immunotherapy Pipeline at AD/PD™ 2025 Conference - Nasdaq
ACIUAC Immune Latest Stock News & Market Updates - Stock Titan
Promising Developments in AC Immune SA’s ACI-7104 Program Drive Buy Rating - TipRanks
AC Immune: Promising Pipeline and Financial Stability Drive Buy Rating - TipRanks
AC Immune (NASDAQ:ACIU) investors are sitting on a loss of 52% if they invested five years ago - Yahoo Finance
AC Immune (NASDAQ:ACIU) Earns “Buy” Rating from HC Wainwright - Defense World
AC Immune SA reports results for the quarter ended December 31Earnings Summary - TradingView
AC Immune SA Reports 2024 Financial Results and Strategic Advances - TipRanks
AC Immune reports FY24 EPS (51c), consensus (54c) - TipRanks
AC Immune Reports Full Year 2024 Financial Results and Provides a Corporate Update - The Manila Times
AC Immune SA Reports 2024 Financial Results and Announces Takeda Partnership for ACI-24.060 - Nasdaq
AC Immune Lands Massive $2.1B Potential Deal with Takeda, Extends Cash Runway to 2027 - StockTitan
AC Immune (ACIU) Projected to Post Quarterly Earnings on Thursday - Defense World
New Strong Buy Stocks for March 5th - Nasdaq
AC Immune to Participate in Upcoming Investor Conferences - GlobeNewswire
AC Immune Management Team Opens Door to Investors at Two Major Healthcare Conferences - StockTitan
AC Immune: Leader In Dementia Therapies, A Space Littered With Failures (ACIU) - Seeking Alpha
Contrasting Silence Therapeutics (NASDAQ:SLN) & AC Immune (NASDAQ:ACIU) - Defense World
Alzheimer's Disease Clinical Trial Pipeline | 110+ Companies Pioneering Breakthroughs in Treatment | - EIN News
AltPep Corporation Appoints Alan Colowick, M.D., M.P.H. To Its Board - citybiz
Down -9.7% in 4 Weeks, Here's Why You Should You Buy the Dip in AC Immune (ACIU) - Yahoo Finance
AltPep Corporation Appoints Alan Colowick, M.D., M.P.H. to Board of Directors - Business Wire
Leerink Partnrs Predicts Increased Earnings for AC Immune - MarketBeat
3 US Penny Stocks With Market Caps Over $100M To Consider - Simply Wall St
Leerink Partnrs Increases Earnings Estimates for AC Immune - Defense World
New Strong Buy Stocks for January 31st - Yahoo Finance
Updates in Therapeutic Development: Clinical Trial Readouts to Watch in the First Half of 2025 - Neurology Live
Five promising small-cap pharmaceutical companies taking on Alzheimer’s - Kursiv Media
AC Immune (NASDAQ:ACIU) & Assembly Biosciences (NASDAQ:ASMB) Head-To-Head Review - Defense World
Down Syndrome Pipeline 2024: Clinical Trials Assessment, FDA Approvals, Therapies, and Key Companies Involved by DelveInsight | Roche, Aelis Farma, AC Immune SA, Eisai Inc., Forest Lab, Eisai Co. - The Globe and Mail
Down Syndrome Pipeline 2024: Clinical Trials Assessment, FDA - openPR
AC Immune (NASDAQ:ACIU) Shares Cross Below Fifty Day Moving AverageTime to Sell? - MarketBeat
Micron Technology (MU-Q) QuotePress Release - The Globe and Mail
Mild Cognitive Impairment Market is Predicted to Advance at a CAGR of 11.6% by 2034 | DelveInsight - The Malaysian Reserve
AC Immune (NASDAQ:ACIU) Shares Down 4.4%Here's What Happened - MarketBeat
US Penny Stocks Spotlight: AC Immune And Two Others To Consider - Simply Wall St
1.23%
1.63%
大文字化:
|
ボリューム (24 時間):